BioHarvest Sciences Inc. (CNVCF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CNVCF representa a BioHarvest Sciences Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 66/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026BioHarvest Sciences Inc. (CNVCF) Resumen de Asistencia Médica y Tuberías
BioHarvest Sciences Inc. operates in the nutraceutical and cannabis sectors, leveraging its proprietary plant cell growth technology to produce and market Vinia, a red grape powder nutraceutical, and medical cannabis. With a focus on international markets, the company aims to deliver plant-based solutions without traditional agricultural methods.
Tesis de Inversión
BioHarvest Sciences Inc. presents a speculative investment opportunity in the nutraceutical and cannabis sectors, driven by its innovative Bioplant technology. The company's potential lies in its ability to efficiently produce plant-based compounds, offering a sustainable alternative to traditional agriculture. Key value drivers include the growth of Vinia sales, expansion into new markets, and the development of novel cannabis-based products. The company's negative P/E ratio of -17.80 and a negative profit margin of -40.9% indicate it is not yet profitable. A beta of 1.49 suggests higher volatility than the market. Upcoming catalysts include potential regulatory approvals for its cannabis products and expansion of its distribution network. However, investors should be aware of the risks associated with operating in the highly regulated cannabis industry and the challenges of scaling production and marketing efforts.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.11B reflects its position as a smaller player in the nutraceutical and cannabis markets.
- Negative P/E Ratio of -17.80 indicates the company is currently not profitable, requiring careful monitoring of its path to profitability.
- Gross Margin of 56.7% suggests strong pricing power and efficient production of its Vinia product.
- Beta of 1.49 indicates higher volatility compared to the overall market, which may appeal to risk-tolerant investors.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth rather than returning capital to shareholders.
Competidores y Pares
Fortalezas
- Proprietary Bioplant technology.
- Established Vinia brand.
- Expertise in cannabis cultivation.
- International operations.
Debilidades
- Limited product portfolio.
- Negative profitability.
- Small market capitalization.
- Reliance on regulatory approvals.
Catalizadores
- Upcoming: Potential regulatory approvals for cannabis products in new markets.
- Ongoing: Expansion of Vinia distribution network through strategic partnerships.
- Ongoing: Development of new cannabis-based products with unique cannabinoid profiles.
- Ongoing: Continued innovation in Bioplant technology to improve efficiency and scalability.
Riesgos
- Potential: Competition from established players in the nutraceutical and cannabis industries.
- Potential: Regulatory changes impacting the cannabis market.
- Potential: Fluctuations in cannabis prices affecting profitability.
- Ongoing: Challenges in scaling production and marketing efforts.
- Ongoing: Dependence on regulatory approvals for cannabis products.
Oportunidades de crecimiento
- Expansion of Vinia Sales: BioHarvest Sciences can increase Vinia sales through targeted marketing campaigns and expansion into new geographic markets. The global nutraceutical market is estimated to reach $441.7 billion by 2026, offering a substantial opportunity for growth. By focusing on e-commerce channels and strategic partnerships with retailers, the company can reach a wider customer base and drive revenue growth. Timeline: Ongoing.
- Development of Novel Cannabis Products: The company can leverage its Bioplant technology to develop novel cannabis-based products with unique cannabinoid profiles. The global medical cannabis market is projected to reach $55.8 billion by 2026. By focusing on research and development, BioHarvest Sciences can create differentiated products that address specific medical needs and capture a share of this growing market. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with established players in the nutraceutical and cannabis industries can accelerate growth and expand market reach. By partnering with distributors, retailers, and research institutions, BioHarvest Sciences can leverage their expertise and resources to commercialize its products more effectively. Timeline: Ongoing.
- Regulatory Approvals: Obtaining regulatory approvals for its cannabis products in key markets can unlock significant growth opportunities. As more countries and regions legalize medical and recreational cannabis, BioHarvest Sciences can capitalize on these opportunities by securing the necessary licenses and permits to operate in these markets. Timeline: Upcoming.
- Technological Innovation: Continued investment in research and development to further enhance its Bioplant technology can create a sustainable competitive advantage. By improving the efficiency and scalability of its production process, BioHarvest Sciences can reduce costs, increase yields, and develop new plant-based products. Timeline: Ongoing.
Oportunidades
- Expansion into new geographic markets.
- Development of novel cannabis products.
- Strategic partnerships.
- Increasing legalization of cannabis.
Amenazas
- Competition from established players.
- Regulatory changes.
- Fluctuations in cannabis prices.
- Economic downturn.
Ventajas competitivas
- Proprietary Bioplant technology for efficient plant cell growth.
- Patents protecting its technology and products.
- Established brand recognition for Vinia in the nutraceutical market.
- Expertise in cannabis cultivation and extraction.
Acerca de CNVCF
BioHarvest Sciences Inc. is a biotechnology company focused on developing and commercializing plant-based products using its proprietary plant cell growth (Bioplant) technology. Founded with the vision of producing high-value plant-based compounds sustainably and efficiently, the company has evolved into a player in both the nutraceutical and cannabis industries. Its core technology allows for the production of active secondary metabolites without the need to grow the entire plant, offering a more controlled and environmentally friendly approach. The company's flagship product, Vinia, is a red grape powder nutraceutical marketed for its antioxidant properties and potential cardiovascular benefits. Vinia is designed to deliver the health benefits of red wine without the alcohol or sugar. In addition to Vinia, BioHarvest Sciences is involved in the development and production of medical cannabis, leveraging its Bioplant technology to cultivate cannabis cells and extract valuable cannabinoids. The company operates internationally, with a focus on markets where nutraceuticals and medical cannabis are legal and regulated. BioHarvest Sciences is based in Vancouver, Canada, and has operations in Israel, where much of its research and development takes place. The company aims to expand its product portfolio and market reach through continued innovation and strategic partnerships.
Qué hacen
- Develops plant cell growth technology to produce active compounds.
- Manufactures and markets Vinia, a red grape powder nutraceutical.
- Cultivates cannabis cells for medical cannabis production.
- Offers plant-based solutions without traditional agriculture.
- Focuses on nutraceutical and cannabis verticals.
- Operates internationally, including Israel and Canada.
Modelo de Negocio
- Produces plant-based compounds using proprietary Bioplant technology.
- Sells Vinia directly to consumers and through retailers.
- Develops and commercializes medical cannabis products.
- Generates revenue through product sales and licensing agreements.
Contexto de la Industria
BioHarvest Sciences Inc. operates within the rapidly evolving nutraceutical and cannabis industries. The nutraceutical market is driven by increasing consumer interest in health and wellness, with a global market size estimated to reach hundreds of billions of dollars. The cannabis industry is experiencing significant growth due to increasing legalization and acceptance of medical and recreational cannabis. BioHarvest Sciences competes with other nutraceutical companies and cannabis producers, including ADOIF (Advanz Pharma Corp), AMEUF (Amneal Pharmaceuticals Inc), COPHF (CorpHQ Inc), CSAMF (Cascadia Acquisition Corp), and EOFBY (Evolus Inc). The company's Bioplant technology offers a potential competitive advantage by providing a more sustainable and efficient production method.
Clientes Clave
- Health-conscious consumers seeking natural supplements.
- Patients using medical cannabis for therapeutic purposes.
- Retailers and distributors of nutraceutical and cannabis products.
- Pharmaceutical companies interested in plant-based ingredients.
Finanzas
Gráfico e información
Precio de la acción de BioHarvest Sciences Inc. (CNVCF): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows Of Monday
· 12 ago 2019
-
Stocks That Fell Through 52-Week Lows Wednesday
· 7 ago 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CNVCF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CNVCF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CNVCF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Ilan Sobel
CEO
Ilan Sobel brings extensive experience in the pharmaceutical and consumer goods industries to his role as CEO of BioHarvest Sciences Inc. His career spans various leadership positions, including roles in marketing, sales, and business development. He has a proven track record of driving growth and innovation in both established companies and startups. Sobel's background includes a strong focus on strategic planning, market analysis, and product commercialization. He is known for his ability to build high-performing teams and execute complex projects.
Historial: Under Ilan Sobel's leadership, BioHarvest Sciences has focused on expanding its Vinia product line and advancing its cannabis program. Key achievements include securing partnerships for distribution and increasing brand awareness. Sobel has overseen the company's efforts to optimize its Bioplant technology and develop new applications for its platform. He has also guided the company through regulatory challenges and market fluctuations.
Información del mercado OTC de CNVCF
The OTC Other tier represents the lowest tier of over-the-counter (OTC) stocks. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for lack of transparency and regulatory oversight. These companies may not be required to file regular reports with the SEC, making it difficult for investors to assess their financial health and business prospects. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure due to OTC listing.
- Lower liquidity and higher price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Difficulty in obtaining reliable information.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Established Vinia brand in the nutraceutical market.
- Proprietary Bioplant technology.
- International operations.
- Experienced management team.
Preguntas Comunes Sobre CNVCF
¿Cuáles son los factores clave para evaluar CNVCF?
BioHarvest Sciences Inc. (CNVCF) actualmente tiene una puntuación IA de 66/100, indicando puntuación moderada. Fortaleza clave: Proprietary Bioplant technology.. Riesgo principal a monitorear: Potential: Competition from established players in the nutraceutical and cannabis industries.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CNVCF?
CNVCF actualmente puntúa 66/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CNVCF?
Los precios de CNVCF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CNVCF?
La cobertura de analistas para CNVCF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CNVCF?
Las categorías de riesgo para CNVCF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established players in the nutraceutical and cannabis industries.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CNVCF?
La relación P/E para CNVCF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CNVCF sobrevalorada o infravalorada?
Determinar si BioHarvest Sciences Inc. (CNVCF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CNVCF?
BioHarvest Sciences Inc. (CNVCF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending for CNVCF, which may provide additional insights.